Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Tissue testing: FDA issues 1guidance on screening donors of cells, tissues and cell- and tissue-based products Feb. 28. The guidelines add three new diseases - West Nile Virus, vaccinia and sepsis - that facilities should test for to those included in a May 2004 draft version. The draft had been released in conjunction with a final donor eligibility rule developed by the agency's biologics center as part of a revamped tissue regulation framework (2"The Gray Sheet" May 24, 2004, p. 11). The new guidance also finalizes components of a 2002 draft guidance with recommendations on reducing the risk of Creutzfeldt-Jakob disease (the human version of "mad cow" disease). Further, it recommends nucleic acid amplification testing for HIV and hepatitis C in both living and cadaveric donors, rather than just the latter; modifies the agency's approach to identifying new "relevant" diseases; and adjusts procedures for communicable disease testing laboratories...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel